Can you switch from Zepbound to retatrutide
Median t max was longer for the fasting (1.75 h) versus reference groups (1.00 h), while no obvious difference was seen for t 1/2 (160 h and 152 h, respectively) between the fasting and reference groups
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors currently undergoing clinical trials
The National Institute for Health and Care Excellence (NICE) recommends individualised treatment targets for HbA1c, commonly aiming for 48 mmol/mol (6.5%) for most adults with type 2 diabetes who are not at significant risk of hypoglycaemia, and 53 mmol/mol (7.0%) for those using medications associated with hypoglycaemia such as insulin or sulfonylureas
Yokoseki A, Shiga A, Tan C-F, Tagawa A, Kaneko H, Koyama A, et al
"GLP-1 Patient Access Report Q3/Q4 2025." FindHonestCare.com BlueCross BlueShield of South Carolina